CLINICAL EVIDENCE Solitaire Revascularization Device

SWIFT PRIME

The SWIFT PRIME¹ study was a global, multicenter, two-arm, prospective, randomized, open, blinded-endpoint (PROBE) trial to compare the functional outcomes in acute ischemic stroke (AIS) subjects treated with either IV t-PA alone or IV t-PA in combination with the Solitaire™ revascularization device.

• Read key findings
• Read original article

STUDY CONCLUSION

In patients receiving intravenous t-PA for acute ischemic stroke with confirmed large-vessel occlusions of the anterior circulation, treatment with the Solitaire™ stent thrombectomy device within 6 hours after symptom onset improved functional outcomes at 90 days.

EXTEND-IA

The EXTEND-IA² trial was an investigator-initiated, multicenter, prospective, randomized, open, blinded-endpoint (PROBE) study in ischemic stroke patients receiving intravenous alteplase within 4.5 hours of stroke onset.

It was conducted to test the hypothesis that anterior circulation ischemic stroke patients, selected with a “dual target” of vessel occlusion and evidence of salvageable tissue on perfusion imaging within 4.5 hours of onset, would have improved reperfusion and early neurological improvement when treated with endovascular thrombectomy using the Solitaire™ FR stent thrombectomy device after intravenous (IV) alteplase, compared to alteplase alone.

• Read key findings
• Read original article

STUDY CONCLUSION

In ischemic stroke patients with a proximal cerebral arterial occlusion and salvageable tissue on CT perfusion imaging, early thrombectomy with the Solitaire™ FR stent thrombectomy device improves reperfusion, early neurologic recovery, and functional outcome compared with alteplase alone.

ESCAPE

The ESCAPE³ trial was an investigator-initiated, multi-center, prospective, randomized, open, blinded-endpoint (PROBE) trial designed to test whether patients with acute ischemic stroke, who were selected on the basis of results of CT and CTA, would benefit from rapid endovascular treatment involving contemporary endovascular techniques.  

Patients were allocated 1:1 to endovascular treatment plus guideline-based care (intervention) vs. guideline-based care alone (control).

• Read key findings
• Read original article

STUDY CONCLUSION

Among acute ischemic stroke patients with proximal vessel occlusion, small infarct core, and moderate-to-good collaterals, rapid endovascular treatment improved functional outcomes and reduced mortality.

REVASCAT

REVASCAT⁴ was an investigator-initiated, multicenter, prospective, randomized, sequential, open, blinded-endpoint (PROBE) study in acute ischemic stroke patients who had contraindications to IV t-PA or had received IV t-PA therapy within 4.5 hours without revascularization after 30 minutes of IV t-PA.

It was conducted to determine the efficacy and safety of neurovascular thrombectomy with the Solitaire™ FR device in conjunction with medical therapy versus medical therapy alone, among eligible acute ischemic stroke patients treatable within 8 hours of symptom onset.

• Read key findings
• Read original article

STUDY CONCLUSION

In patients with anterior circulation stroke treatable within 8 hours of symptom onset, stent retriever thrombectomy reduces post-stroke disability and increases the rate of functional independence.

MR CLEAN

MR CLEAN⁵ was a randomized trial of intra-arterial treatment (IAT) for acute stroke. In patients with acute ischemic stroke caused by proximal intracranial arterial occlusion, IAT is highly effective for emergent revascularization. Five hundred patients with a proximal arterial occlusion in the anterior cerebral circulation demonstrated on vessel imaging, treated with IAT within 6 hours were randomized to IAT plus usual care (IV t-PA or medical management) or usual care alone.

• Read key findings
• Read original article

STUDY CONCLUSION

The MR CLEAN study observed that the addition of stent thrombectomy for acute ischemic stroke care is safe and effective when administered within 6 hours of symptom onset.